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Abstract
Protein kinase C (PKC) modulates growth, differentiation,
and apoptosis in a cell-specific fashion. Overexpression of
PKC-a in MCF-7 breast cancer cells (MCF-7-PKC-a cell)
leads to expression of a more transformed phenotype. The
response of MCF-7 and MCF-7-PKC-c cells to phorbol es-
ters (TPA) was examined. TPA-treated MCF-7 cells demon-
strated a modest cytostatic response associated with a G,
arrest that was accompanied by Cipl expression and retino-
blastoma hypophosphorylation. While p53 was detected in
MCF-7 cells, evidence for TPA-induced stimulation of p53
transcriptional activity was not evident. In contrast, TPA
treatment induced death of MCF-7-PKC-a cells. Bryostatin
1, another PKC activator, exerted modest cytostatic effects
on MCF-7 cells while producing a cytotoxic response at low
doses in MCF-7-PKC-a cells that waned at higher concen-
trations. TPA-treated MCF-7-PKC-a cells accumulated in
G2/M, did not express p53, displayed decreased Cipl expres-
sion, and demonstrated a reduction in retinoblastoma hypo-
phosphorylation. TPA-treated MCF-7-PKC-a cells ex-
pressed gadd45 which occurred before the onset of
apoptosis. Thus, alterations in the PKC pathway can modu-
late the decision of a breast cancer cell to undergo death
or differentiation. In addition, these data show that PKC
activation can induce expression ofgadd45 in a p53-indepen-
dent fashion. (J. Clin. Invest. 1995. 96:1874-1886.) Key
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Introduction
The protein kinase C (PKC)1 gene family lies on signal trans-
duction pathways regulating growth and differentiation in a
variety of cell types ( 1, 2). In addition, activation of this signal-
ing pathway modulates induction of apoptosis in a cell-specific
fashion. In certain cells, phorbol ester-stimulated activation of
PKC inhibits apoptosis while in other cells a death program is
initiated by activation of PKC (3-7). Beyond describing the
ability of PKC to modulate apoptosis, little is known of the
mechanisms either within the PKC pathway or signaling cas-
cades distal to PKC that are responsible for producing these
disparate, cell-specific responses. The existence of at least 12
members in the PKC gene family may, in part, serve as a
mechanism responsible for the diverse responses elicited by
activating this pathway ( 1, 2). Differences in substrate specific-
ity, subcellular localization, and sensitivity to agonist-induced
downregulation among the individual PKC isoforms may serve
as possible mechanisms by which these varied cellular re-
sponses are elicited (1, 2). Thus, the array of isoforms ex-
pressed by a cell may determine its response to PKC activation.
In addition to the array of isoforms initially expressed, cellular
responses requiring chronic activation of the PKC pathway may
also be influenced by the different sensitivities of individual
isoforms to activation-induced proteolytic downregulation. Al-
ternatively, differences in pathways activated by and distal to
PKC that control growth, differentiation, and apoptosis could
underlie the diversity of cellular responses to PKC activation.
A role for PKC in modulating growth of breast neoplasms
has been suggested from various observations (8-15). To di-
rectly examine a role for PKC in altering the growth of breast
cancer cells, we have generated a MCF-7 human breast cancer
cell line that was stably transfected with and overexpresses
PKC-a (MCF-7-PKC-a cells). In comparison to the parental
MCF-7 cell, the MCF-7-PKC-a cell displays a more trans-
formed, aggressive phenotype as evidenced by an increased
proliferative rate, anchorage-independent growth, loss of an epi-
thelioid appearance, downregulation of estrogen receptor ex-
pression, and enhanced tumorigenicity with metastatic potential
in nude mice ( 16). These findings demonstrated that alterations
in the PKC pathway are associated with significant changes in
the proliferative capacity and differentiation status of breast
cancer cells.
Given the significant phenotypic alterations observed in
MCF-7-PKC-a cells, it was of interest to examine the response
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of this cell to phorbol ester-stimulated activation of PKCs.
Parental MCF-7 cells treated with tetradecanoyl phorbol-13-
acetate (TPA) exhibited modest growth inhibition with reten-
tion of viability that was associated with sustained induction of
Cipl, extensive hypophosphorylation of retinoblastoma (Rb),
and an accumulation of cells in G1. In contrast, TPA induced
death of MCF-7-PKC-a cells. MCF-7-PKC-a cells accumulated
in G2/M, transiently expressed only low levels of Cipl, and
lacked a substantial degree of Rb hypophosphorylation. While
eliciting only a modest cytostatic response in MCF-7 cells, bry-
ostatin 1 exerted cytotoxic effects in MCF-7-PKC-a cells at
low doses. This response was not seen at higher concentrations
of this agent and high doses of bryostatin 1 inhibited MCF-7-
PKC-a death induced by TPA. Preceding the onset of death
and possibly involved in mediating this process, TPA-treated
MCF-7-PKC-a cells expressed high levels of gadd45 mRNA
transcripts. Expression of gadd45 was not induced by TPA in
MCF-7 cells. Thus, associated with changes in PKC isoform
expression was the conversion from a modest cytostatic effect
observed in TPA-treated parental MCF-7 cells to death of MCF-
7-PKC-a cells exposed to the phorbol ester.
Methods
Cell culture. MCF-7 cells were purchased from the American Type
Culture Collection (Rockville, MD). MCF-7-PKC-a cells have been
described elsewhere (16) and were generated by stably cotransfecting
MCF-7 cells with PKC-a subcloned into the pSV2M(2)6 vector (17)
and a neomycin resistance plasmid. The stable transfectants were pooled
and expanded as a heterogenous group. Cells stably transfected with
the empty pSV2M(2)6 vector were also generated (vector-transfected
cells). Cells were grown in DME supplemented with 2 mM glutamine,
10 mM 4-[2-hydroxyethyl] -1-piperazinethanesulfonic acid, 10% fetal
calf serum, 50 U/ml penicillin, and 50 jg/ml streptomycin. For cell
growth experiments, 7.5 x 103 cells/ml were incubated in 24-well plates
with replicates of 6 wells per treatment. Cell counts were done using a
Coulter counter (Coulter Corp., Hialeah, FL). Bryostatin 1 was isolated
from Bugula neritina as described (18).
Propidium iodide viability assay. Approximately 5 X I0O cells were
resuspended in 1 ml of media. 20 1.d of propidium iodide stock solution
(500 j.g/ml propidium iodide in 38 mM Na citrate solution) per milliliter
of cell suspension was added to achieve a final propidium iodide concen-
tration of 10 Ag/ml. Samples were held at room temperature and ana-
lyzed immediately on a FACScan® flow cytometer (Becton Dickinson
Immunocytometry Systems, Mountain View, CA). Statistical analysis
was performed by simultaneously displaying on 2-parameter dot plots,
red fluorescence versus forward scatter. Regions were assigned to the
different populations displayed in the red fluorescence versus forward
scatter histograms. The percentage of cells in each population was calcu-
lated using region statistics.
Microscopy. Cells maintained in culture were photographed at a
magnification of 320 with a Nikon Diaphot inverted microscope. For
structural analysis, cells were fixed for 30 min in 2.5% (vol/vol) glutar-
aldehyde and 0.1 M phosphate buffer (pH 7.4). After postfixation in
1% (wt/vol) osmium tetroxide, cells were dehydrated through a graded
series of alcohol and propylene oxide and embedded in Epon. Thick
sections were stained with Richardson's stain. Thin sections (< 90 nm)
were stained with uranyl acetate and lead citrate and examined with a
Jeol-1200 EX electron microscope.
DNA extraction and electrophoresis. Total cellular DNA was iso-
lated as described previously, with minor revisions (19). Cells (1.5
x 107) were washed and resuspended in 0.5 ml of lysis buffer (50 mM
Tris, 10 mM EDTA, 0.5% Triton X-100) with 5 mg/ml proteinase K
and incubated at 370C for 12 h. Lysates were then brought to a volume
of 2.5 ml with lysis buffer and extracted twice with phenol-chloroform.
DNA was then precipitated with 0.1 vol of 3 M sodium acetate and 3
vol of ethanol at -20TC for 12 h. DNA was resuspended in 10 mM
Tris (pH 8.0) with 0.1 mM EDTA and digested with 0.2 mg of RNase
A for 2 h at 370C. Approximately 20 Itg of each sample of total DNA
was size fractionated on a 2% agarose gel, stained with ethidium bro-
mide, and photographed by ultraviolet translumination to assess DNA
fragmentation.
Cell cycle analysis. Cells were trypsinized, washed, resuspended in
phosphate buffered saline, and fixed in 70% ethanol at 40C for 30 min.
Propidium iodide (50 pg/ml) in citrate buffer was added to the fixed
cells and analysis was performed using a FACScan® flow cytometer.
Analysis was done on 104 cells.
Northern blot analysis. Total RNA was extracted using TRIzol re-
agent (GIBCO BRL, Gaithersburg, MD) as per instructions of the manu-
facturer. Northern blot analysis was done as we have described pre-
viously (20). The p53 probe was purchased from the American Type
Culture Collection. Other cDNA probes were kindly donated by Dr.
Albert Fornace, Jr. (gadd45) and Dr. Steven Elledge (Cipl ).
Western blot analysis. Hot Laemmli lysis buffer supplemented with
50 mM NaF was directly added to cells pelleted by centrifugation. The
samples (105 cells/ 10 Il) were treated at 1100C for 5 min. Western
blot analysis was performed as described previously (21 ) with 105 cells
per lane. Antisera to p53 (Oncogene Science Inc., Manhasset, NY) and
Rb (Santa Cruz Laboratories, Santa Cruz, CA) were used per instruc-
tions of their respective manufacturers. Enhanced chemiluminescence
was used to detect the antigen-antibody complexes.
Southern blot analysis. DNA was extracted, exhaustively digested
with BamHI, EcoRl, HindIII, and XbaI, subjected to agarose electro-
phoresis in a 0.6% gel, and transferred to filters. Random primer-labeled
p53 was hybridized to the filters under standard conditions. Autoradiog-
raphy was used to detect p53 digestion products.
Transient transfection analysis. This analysis was done as published
elsewhere (21). Briefly, cells were plated 1 d before transfection. Cal-
cium phosphate technique was used to transfect the cells with a reference
/3-galactosidase plasmid (3 pg), the chloramphenicol acetyl transferase
(CAT) reporter construct (10 pg), and other appropriate cDNAs. The
total DNA transfected was adjusted with carrier DNA to bring the final
DNA content to 20 Hg. After an overnight incubation, the cells were
washed and placed in fresh media. Where indicated, phorbol esters were
added after the cells were placed in fresh media. 40 h after transfection,
extracts were prepared and 63-galactosidase and CAT activities were
determined (21 ). CAT values were normalized to P-galactosidase activ-
ity to control for variation in transfectional efficiency. Transfections
were done in triplicate. The 63-galactosidase plasmid was purchased
from CLONTECH (Palo Alto, CA). The p53-responsive, PG-13-CAT
reporter construct and its non-p53-responsive, mutated construct (MG-
15-CAT) were generously donated by Dr. Bert Vogelstein. The p53
promoter-CAT reporter construct (p0.5 CAT) and wild-type and mutant
p53 expression constructs have been described previously (22).
Nuclear run-on analysis. Nuclei (250 pg) extracted by standard
techniques and 250 /Ci [a- 32P]UTP were used for run-on transcription
assays. Using previously published techniques (23), equal concentra-
tions of 32P-labeled RNA were hybridized to Hybond-N filters on which
the appropriate cDNA fragments (2 ,ug/slot) had been hybridized. Hy-
bridization of nascent RNA was normalized to the genomic signal.
Quantitation of the signal was performed using a Phosphorlmager (Mo-
lecular Dynamics, Inc., Sunnyvale, CA) with Image Quant' software.
Transforming growth factor-,6 cDNA obtained from the American Type
Culture Collection was used as an internal control since its expression
was not altered in MCF-7-PKC-a cells nor in MCF-7 cells by TPA
treatment (data not shown).
Results
MCF-7-PKC-a cells undergo death in response to TPA. In the
absence of TPA, MCF-7-PKC-a_ cells proliferated at a higher
rate than did vector-transfected or MCF-7 cells (MCF-7,
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Figure 1. Effects of TPA
on growth of MCF-7 and
MCF-7-PKC-a cells.
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64,200; vector-transfected, 67,920; and MCF-7-PKC-a,
379,250 cells after 5 d in non-TPA-containing media). In re-
sponse to phorbol ester treatment, growth of MCF-7 and vector-
transfected cells was modestly decreased (Fig. 1). While prolif-
eration of MCF-7-PKC-a cells was inhibited to a greater degree
than in parental and vector-transfected MCF-7 cells, the sensi-
tivity of parental/vector-transfected MCF-7 and MCF-7-PKC-
a cells to phorbol ester-induced growth inhibition was similar.
To examine whether differences in the rate of cell death
were responsible for the enhancement in TPA-induced growth
inhibition of MCF-7-PKC-a cells, the viability status of phorbol
ester-treated cells was examined. Due to extensive clumping
of nonadherent, TPA-treated MCF-7-PKC-a cells, it was diffi-
cult to quantitate cellular viability using trypan blue exclusion.
Viability of cells was examined by FACS® analysis using pro-
pidium iodide exclusion as a measure of cellular integrity (24).
Flow cytometric analysis provided a better dispersion of cells
and allowed a more precise means to quantitate viability. Viable
cells exclude propidium iodide and display an appropriate de-
gree of forward scatter for an intact cell (see R2 gate in Fig.
2). Other populations of cells display either an intense increase
in propidium iodide uptake with large variations in forward
scatter (see R1 gate in Fig. 2) or a moderate increase in propid-
ium iodide uptake with varying decreases in forward scatter
(see R3 gate in Fig. 2). The increase in propidium iodide uptake
of cells gating into the RI and R3 regions is consistent with
loss of membrane integrity while the reduced forward scatter
suggests either cellular condensation or fragmentation. Micro-
scopic analysis of cells sorted from these regions demonstrated
that intact, normal appearing cells were contained in the R2
region while debris with stripped nuclei and significantly con-
densed cells were found in the Ri and R3 regions, respectively
(data not shown).
In untreated MCF-7 and MCF-7-PKC-a cells, the vast ma-
jority of cells excluded propidium iodide and displayed a degree
of forward light scatter indicative of an intact cell (see R2
region in Fig. 2, A and C). After a 72-h exposure to 10 nM
TPA, the majority of parental MCF-7 cells excluded propidium
iodide and displayed approximately the same size characteristics
as did untreated cells (Fig. 2B). The proportion of events gated
into the RI and R3 regions in TPA-treated parental MCF-7 cells
was not significantly increased. In contrast, TPA-treated MCF-
7-PKC-a cells displayed a significant reduction in viable, pro-
pidium iodide-excluding cells gating into the R2 region. A
significant proportion of MCF-7-PKC-a cells exposed to TPA
developed either an intense increase in propidium iodide uptake
(RI region) or a moderate increase in propidium iodide uptake
with a reduction in forward scatter (R3 region). Qualitatively
similar decreases in membrane integrity and loss of viability
were observed in TPA-treated MCF-7-PKC-a cells using trypan
blue exclusion (data not shown). A significant decrease in via-
bility of MCF-7-PKC-a cells exposed to 10 nM TPA, as defined
by a loss of propidium iodide-excluding cells gated to the RI
region, was observed after a 12-h exposure to 10 nM TPA and
was maximal after a 24-48-h exposure to this agent (Fig. 3A).
In contrast, only minimal decreases in viability of parental or
vector-transfected cells were seen after TPA treatment. After a
48-h exposure, MCF-7-PKC-a cell death was maximal at a TPA
concentration of 10 nM (Fig. 3B). Thus, increases in cell death
were responsible for the more profound growth inhibition ob-
served in TPA-treated MCF-7-PKC-a cells.
Bryostatin I displays concentration-dependent, biphasic ef-
fects on growth ofMCF-7-PKC-ca cells. Bryostatin 1, a macro-
cyclic lactone, has completed phase I trials and is currently
undergoing clinical evaluation as an antineoplastic agent in
phase II studies (25, 26). While bryostatin 1 is believed to
exert its effects by activating the PKC pathway, it can either
mimic or antagonize the effects of phorbol esters in a cell-
specific fashion (27). In certain cell types, effects exerted by
bryostatin 1 at low doses dissipate as the concentration is in-
creased (28-32). The dose- and cell type-specific responses
of bryostatin 1 are thought to be due to preferential up- or
downregulation of specific isoforms involved in mediating the
effects of TPA and bryostatin 1 (28-33).
While eliciting only minimal growth inhibition in parental
MCF-7 cells that waned at higher concentrations (Fig. 4 A),
bryostatin 1 displayed significant, concentration-dependent anti-
proliferative effects in MCF-7-PKC-a cells (Fig. 4 B). The
maximal degree of MCF-7-PKC-a growth inhibition induced
by TPA was reached at a concentration of 1 nM and remained
constant with exposures of 1,000 nM (Fig. 4 B). In contrast,
the growth inhibitory effects of bryostatin 1 significantly waned
at concentrations 2100 nM. To examine whether growth inhibi-
tion of MCF-7 and MCF-7-PKC-a cells induced by bryostatin
1 was due to a cytostatic or cytotoxic mechanism, cellular via-
bility was examined (Fig. 4, C and D). MCF-7 cells retained
viability upon exposure to 10 nM TPA or bryostatin 1, a concen-
tration that maximally inhibited growth of these cells (Fig. 4
C). In contrast, MCF-7-PKC-a cells displayed a temporally
dependent reduction in viability when exposed to either 10 nM
TPA or bryostatin 1 (Fig. 4 D). As with TPA, MCF-7 and
MCF-7-PKC-a cells responded to low doses of bryostatin 1 in
qualitatively dissimilar fashions exhibiting cytostatic and cyto-
toxic responses, respectively.
The ability of high bryostatin 1 concentrations to interfere
with TPA-induced death of MCF-7-PKC-a cells was examined.
TPA significantly inhibited growth and reduced the viability of
MCF-7-PKC-a cells (Fig. 5, A and B, respectively). Incubation
with 1,000 nM bryostatin 1 inhibited growth of MCF-7-PKC-
a cells but not to the extent seen with TPA treatment (Fig. 5
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Figure 2. TPA treatment induces death of MCF-7-PKC-a cells. MCF-7 (A and B) and MCF-7-PKC-a cells (C and D) were treated with vehicle
(A and C) or 10 nM TPA (B and D) for 72 h. Cells were harvested and exposed to propidium iodide. Forward light scatter (see ordinate) and
propidium iodide uptake (see abscissa) were measured. Cells were gated into separate areas representing: RI, high propidium iodide uptake with
variable forward scatter; R2, low propidium iodide uptake and appropriate forward scatter for intact cells; and R3, reduced forward scatter consistent
with debris and/or enhanced propidium iodide uptake. This experiment was repeated with similar results. Vector-transfected cells gave identical
results to MCF-7 cells.
A). Unlike the extensive cell death that occurred after exposure
to 10 nM bryostatin 1, viability of MCF-7-PKC-a cells treated
with 1,000 nM bryostatin 1 was essentially unaffected and com-
parable to that of vehicle-treated cells (Fig. 5 B). In cells coin-
cubated with these agents, high concentrations of bryostatin 1
exerted dominant effects over TPA and blocked death induced
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by the phorbol ester. Growth and viability of cells coincubated
with these agents was identical to that seen in MCF-7-PKC-a
cells treated only with 1,000 nM bryostatin 1 (Fig. 5, A and
B). Thus, high concentrations of bryostatin 1 were able to inter-
fere with the signal transduction pathway used by TPA to induce
MCF-7-PKC-a cell death.
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Figure 3. Time- and concentration-dependent death of TPA-treated MCF-7 cells. MCF-7 (e), vector-transfected (a), and MCF-7-PKC-a (A) cells
were treated with 10 nM TPA for varying times (A) or varying TPA concentrations for 24 h (B). Cellular viability was measured using the
propidium iodide exclusion assay with viable cells defined as those gating into the R2 region that exclude propidium iodide and display the
appropriate degree of forward scatter for an intact cell. Viable cell number is expressed on the ordinate with 100% equaling the percentage of non-
TPA-treated cells gating to the R2 region. These experiments were repeated with similar results.
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Figure 4. Effects of bryostatin 1 on MCF-7
and MCF-7-PKC-a cell growth and viability.
MCF-7 (A) and MCF-7-PKC-a (B) cells
were exposed to varying concentrations of
TPA (o) or bryostatin I (.) (see abscissa)
D and cell counts were done 5 d after treatment.
MCF-7 (C) and MCF-7-PKC-a (D) cells
were treated with 10 nM TPA (o) or bryo-
statin 1 (.) for varying times (see abscissa)
and cell viability was measured. Viability is
expressed as a percentage of total cell num-
ber with 100% equaling the viability of un-
treated cells. Replicates of six and three were
obtained for each point representing cell
counts and viability determinations, respec-
p tively. Similar results were obtained in other
72 9 experiments. Vector-transfected cells gave
similar results to those obtained with parental
MCF-7 cells.
Morphologic changes associated with TPA-induced death
ofMCF-7-PKC-a cells occur in the absence ofDNA degrada-
tion into oligonucleosomal units. MCF-7 cells grew adherent
to the plastic surface and exhibited an epithelioid appearance
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with retention of the normal cellular architecture. MCF-7-PKC-
a cells proliferated in suspension devoid of an epithelioid mor-
phology (Fig. 6 C). Exposure of MCF-7-PKC-a cells to TPA
Figure 5. High concentrations of bryostatin
1 inhibit TPA-induced death of MCF-7-
PKC-a cells. MCF-7-PKC-a cells were ex-
posed for 5 d to vehicle, 10 nM TPA, 1,000
nM bryostatin 1, or both agents (see below
the figure). In cells treated with both agents,
bryostatin 1 was added 6 h before TPA. Cell
counts (A) and viability determinations (B)
were done. Replicates of six and three were
obtained for each point representing cell
_- counts and viability determinations, respec-
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+ tively. Similar results were obtained in sepa-
+ + rate experiments.
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Figure 6. TPA- and bryostatin 1-induced morphologic changes in MCF-
7-PKC-a cells. Inverted microscopy was done on vehicle-treated MCF-
7 (A) and MCF-7-PKC-a (C). MCF-7 and MCF-7-PKC-a cells treated
with 100 nM TPA for 72 h are shown in B and D, respectively. Micro-
scopic analysis was also performed on MCF-7-PKC-a cells treated for
72 h with 10 nM bryostatin 1 (E) and 1,000 nM bryostatin 1 in the
absence (F) or presence (G) of 10 nM TPA. When coincubated with
TPA, bryostatin 1 was added 6 h before the phorbol ester. Similar
observations were made in other experiments. Vector transfected MCF-
7 cells behaved in an identical fashion to MCF-7 cells in response to
TPA.
was associated with extensive clumping (data not shown) and
vacuolization (Fig. 6 D). A minority of TPA-treated MCF-7-
PKC-a cells adhered tightly to the plastic surface, displayed
prominent vacuolization, and assumed a fibroblast-like appear-
ance (Fig. 6 D). Exposure to 10 nM bryostatin 1 induced only
rare fibroblast-like adherent cells and a much lesser degree of
vacuole formation (Fig. 6 E). Small evaginations from the
plasma membrane were seen in cells treated with 10 nM bryo-
statin 1 (Fig. 6 E). MCF-7-PKC-a cells treated with 1,000 nM
bryostatin 1 in the absence (Fig. 6 F) or presence (Fig. 6 G)
of 10 nM TPA closely resembled untreated MCF-7-PKC-a
cells. In addition, the plasma membrane evaginations seen in
cells treated with doses of bryostatin 1 inducing death (10 nM)
were not evident in cells treated with high concentrations of
this agent. Thus, high doses of bryostatin 1 failed to elicit the
same effects seen with lower concentrations of this agent and
exerted dominant effects over TPA-induced morphologic
changes in MCF-7-PKC-a cells.
Using Richardson's stain, sectioned MCF-7 (Fig. 7 A) and
MCF-7-PKC-a (Fig. 7 B) cells were examined. TPA treatment
of MCF-7-PKC-a cells was associated with nuclear and cellular
condensation and cell blebbing (Fig. 7 B). Similar changes
were not seen in TPA-treated MCF-7 cells (Fig. 7 A). Thus, in
contrast to MCF-7 cells, MCF-7-PKC-a cells displayed certain
signs indicative of apoptosis (e.g., cellular/nuclear condensa-
tion plasma membrane and blebbing) in response to TPA. Elec-
tron microscopy indicated that the extensive vacuolization of
TPA-treated MCF-7-PKC-a cells was due to lysosomal swell-
ing (Fig. 7 C). The role, if any, of the lysosomal enlargement
in TPA-induced apoptosis of MCF-7-PKC-a cells is uncertain.
Although the development of translucent cytoplasmic vacuoles
has been described in apoptosis, lysosomal swelling to the de-
gree observed in TPA-treated MCF-7-PKC-a cells is not usually
considered as a morphologic feature of apoptosis (34). Treat-
ment with 10 nM bryostatin 1 which produced a similar degree
of MCF-7-PKC-a death as did 10 nM TPA (Fig. 4 D) was
associated with a much lesser degree of lysosomal swelling
(Fig. 6 E). As assessed by staining sectioned cells with Richard-
son's stain, low-dose bryostatin 1 treatment produced the same
cell blebbing (possibly corresponding to the plasma membrane
evaginations seen with inverted microscopy) and cellular/nu-
clear condensation (data not shown). The lysosomal swelling
seen in TPA-treated MCF-7-PKC-a cells could be a unique
morphologic feature associated with the death of these cells.
Alternatively, this event could be due to the differences in PKC
isoform expression between MCF-7-PKC-a and MCF-7 cells
and their effect on the lysosomal response to TPA-induced acti-
vation. However, the ability of 10 nM TPA and bryostatin 1 to
elicit different degrees of lysosomal swelling in MCF-7-PKC-
a cells and yet to stimulate a similar extent of cell death suggests
that the pronounced swelling was due to a primary alteration
in the lysosomal response to TPA rather than being associated
with the death process.
Given the association of DNA fragmentation into oligo-
nucleosomal units with apoptosis, this parameter was examined
in MCF-7-PKC-a cells (Fig. 8). Despite the morphologic evi-
dence suggestive of apoptosis in TPA-treated MCF-7-PKC-a
cells, degradation of DNA into oligonucleosomal units was not
detected after phorbol ester treatment of these cells. Certain
cells undergoing apoptosis have been reported to exhibit DNA
degradation yielding high molecular weight fragments in the
absence of further degradation to form oligonucleosomal units
(35). Thus our inability to detect DNA degradation into oligo-
nucleosomal units does not necessarily imply the absence of
DNA fragmentation in TPA-treated MCF-7-PKC-a cells.
TPA induces dissimilar cell cycle alterations in MCF-7 and
MCF-7-PKC-ar cells. A time-dependent accumulation of MCF-
7 cells in G1 was observed with TPA treatment (Fig. 9 A). In
contrast, TPA treatment elicited a prominent accumulation of
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Figure 7. TPA-treated MCF-7-PKC-a cells display cellular
condensation and prominent vacuole formation. MCF-7 (A)
and MCF-7-PKC-a (B) cells were treated with 10 nM TPA
for 72 h. Staining of sectioned cells was done with Richard-
son's stain. In C, electron microscopy was done on MCF-
7-PKC-a cells treated with 10 nM TPA for 72 h. The arrows
in C indicate the swollen lysosomes. Similar results were
obtained in separate experiments. Vector-transfected cells
responded to TPA treatment in a similar manner as did
MCF-7 cells.
MCF-7-PKC-a cells in G2/M (Fig. 9 B). Thus, the dissimilar
response of MCF-7 and MCF-7-PKC-a cells to TPA suggested
that differences exist in the factors mediating phorbol ester-
induced modulation of cell cycle check points.
MCF-7-PKC-a cells lack p53. Given the prominent role of
p53 in controlling cell cycle progression from GI to S phase
and its ability to stimulate cell death (36-38), the status of this
protein in MCF-7 and MCF-7-PKC-a cells was assessed. Using
Northern blot analysis, p53 mRNA transcripts were readily de-
Cell: MCF-7 MCF-7-PKC U.
Duration of TPA
Exposure(hr): 0 6 12 24 48 0 6 12 24 48
-Figure 8. TPA-treated MCF-7-PKC-a cells undergo death without form-
ing an oligonucleosomal DNA ladder. MCF-7 and MCF-7-PKC-a cells
were treated for varying times with 100 nM TPA (see above the gel).
DNA was extracted and subjected to agarose electrophoresis. The migra-
tion of molecular weight indicators is shown on the far right. This
experiment was repeated on several occasions with similar results. Vec-
tor-transfected cells responded to TPA treatment in a similar manner as
did MCF-7 cells.
tected in vector-transfected and MCF-7 cells (Fig. 10). How-
ever, levels of p53 mRNA transcripts were negligible in MCF-
7-PKC-a cells (Fig. 10 A). Using Western blot analysis, a
concomitant reduction in the content of p53 protein was ob-
served in MCF-7-PKC-a cells relative to those levels found in
MCF-7 and vector-transfected cells (Fig. 10 B). To examine
whether a gross p53 gene rearrangement occurred in MCF-7-
PKC-a cells that could explain its loss of expression, Southern
blot analysis was performed. The use of multiple restriction
enzymes that cut within the p53 locus (BamHI, EcoRI, HindIII,
and XbaI) failed to reveal any gross rearrangement of the p53
gene (data not shown). To directly assess the transcriptional
status of factors controlling expression of p53, transient trans-
fection assays were performed using a p53 promoter-reporter
CAT construct (pO.5 CAT). The p53 promoter region sub-
cloned into the reporter construct includes nucleotides -320 to
+210 relative to the transcriptional start site and has been shown
to be activated by p53 (22). After normalization to 3-galactosi-
dase activity to control for differences in transfectional effi-
ciency, a significant basal induction of CAT expression con-
trolled by the p53 promoter was evident in MCF-7 cells (Fig.
11 A). In MCF-7-PKC-a cells, basal levels of pO.5 CAT activity
were negligible (Fig. 11 A). Transient overexpression of p53
in MCF-7 cells further enhanced activity of pO.5 CAT while
expression of an inactive p53 mutant did not significantly stimu-
late pO.5 CAT activity. In MCF-7-PKC-a cells, expression of
p53 stimulated pO.5 CAT activity to a lower absolute level than
in MCF-7 cells but to a similar degree relative to the fold
increase over basal (three- and sixfold over basal in MCF-7
and MCF-7-PKC-a cells, respectively). Stimulation of pO.5
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Figure 9. Cell cycle differences in
TPA-treated MCF-7 and MCF-7-
HRS PKC-a cells. MCF-7 (A) and
MCF-7-PKC-a (B) cells were
treated with 100 nM TPA for
varying periods of time indicated
above the histograms, and cell cy-
cle distribution was analyzed by
propidium iodide staining. These
results were obtained in other ex-
periments. Vector-transfected
cells gave results identical to those
obtained with MCF-7 cells.
CAT activity by p53 expression in MCF-7-PKC-a cells was
specific since cotransfection with the inactive p53 mutant failed
to enhance this activity. Thus, the marked reduction in p53
mRNA transcripts contained in MCF-7-PKC-a cells could, in
part, be explained by a reduction in the transcription of this
gene as indicated by the decreased p53-promoter CAT reporter
activity in these cells.
Functional p53 activity was assessed using the PG-13-CAT
construct that contains multiple copies of the consensus p53
response element. In MCF-7 cells transiently transfected with
the PG-13-CAT construct, significant activation of the reporter
was evident (Fig. 11 B). MCF-7 cells transfected with the
mutant, non-p53-responsive construct (MG-1S-CAT) dis-
played negligible levels of CAT activity. In MCF-7-PKC-a
cells, similar low levels of CAT activity were expressed from
either PG-13-CAT or MG-1S-CAT. Thus, MCF-7-PKC-a cells
displayed a large reduction in functional p53-directed transcrip-
tional activity.
Phorbol esters induce Cip] expression in MCF-7 cells while
gadd45 is strongly induced in MCF-7-PKC-a cells. Given the
ability of Cipl/WAFl/p21 to arrest cells in GO/GI (39, 40)
and the association of Cipl and gadd45 expression with cell
death (41-45), we examined their expression in TPA-treated
MCF-7 and MCF-7-PKC-a cells (Fig. 12). TPA-treated MCF-
efi ' .0fi 0RS6, ,
qIV 4e; ;
p 53
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Figure 10. MCF-7-PKC-a cells exhibit decreases in p53 content. North-
ern (A) and Western (B) blot analysis were done on MCF-7-PKC-a,
MCF-7 vector-transfected, and MCF-7 cells. The derivation of the sam-
ples is indicated above the autoradiograms. Each experiment was re-
peated with similar results.
7 cells displayed a significant induction of CipI that temporally
coincided with growth arrest and accumulation of cells in GI
(Fig. 12 A). A modest induction of CipI was detected in TPA-
treated MCF-7-PKC-a cells. However, TPA failed to stimulate
a sustained expression of Cipl in MCF-7-PKC-a cells. In con-
trast, TPA treatment of MCF-7-PKC-a cells markedly stimu-
lated expression of gadd45 (Fig. 12 A). Only a modest TPA-
induced increase in gadd45 was detected in MCF-7 cells. The
increase in gadd45 in MCF-7-PKC-a cells (2-4 h) temporally
preceded the onset of decreases in viability occurring at 12 h
(Fig. 3 A). Using nuclear run-on analysis, basal transcriptional
activity of gadd45 was shown to be significantly increased
(t 8.8-fold) in MCF-7-PKC-a cells relative to MCF-7 cells
(Fig. 12 B). While gadd45 transcription was not stimulated by
TPA in MCF-7 cells, a 2.6-fold increase in transcription of this
gene was observed in MCF-7-PKC-a cells within a 30-min
exposure to TPA (Fig. 12 B). Transcription of gadd45 in MCF-
7-PKC-a cells remained elevated above the basal levels even
12 h after exposure to TPA. The inability of TPA to induce
gadd45 expression in MCF-7-PKC-a cells pretreated with
cycloheximide demonstrated that induction of this gene required
ongoing protein synthesis (Fig. 12 C).
TPA-induced expression of Cip] in MCF-7 cells was not
associated with an increase in p53-dependent transcriptional
activity. Expression of Cipl and gadd45 can be mediated by a
p53-dependent pathway (39-41, 46, 47). To examine whether
TPA used a p53-dependent mechanism to induce expression of
these genes, the content of p53 and functional status of this
pathway were analyzed in TPA-treated cells. TPA treatment of
MCF-7 cells elicited a temporally dependent reduction in p53
mRNA transcripts (Fig. 13 A). In MCF-7-PKC-a cells, p53
mRNA transcripts were not detected in the basal state nor were
they induced upon TPA treatment. To assess the functional
consequences of the TPA-induced reduction in p53 mRNA tran-
scripts in MCF-7 cells, expression of the p53-responsive PG-
13-CAT construct was examined after TPA treatment (Fig. 13,
B and C). Treatment of MCF-7 cells with 10 or 100 nM TPA
reduced the activity of the p53-responsive, PG-13-CAT con-
struct (Fig. 13 C). Given the possibility that TPA may acutely
activate and then later repress p53-dependent transcriptional
activity, the effects of varying the duration of TPA exposure to
MCF-7 cells transiently transfected with the PG-13 reporter
were examined. Whether added for the entire period (48 h) or
only the final 24 h, TPA did not activate the PG-13 reporter
construct and, in fact, possessed significant inhibitory properties
(Fig. 13 C). Under these treatment conditions, TPA did not
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Figure 11. MCF-7-PKC-a cells display reductions in p53 functional activity. In A, MCF-7 and MCF-7-PKC-a cells (see below the figure) were
transiently cotransfected with p.05 CAT reporter and 13-galactosidase reference plasmid in the absence or presence of p53 wild-type or mutant
expression vectors (see below figure). CAT activity was normalized to ,3-galactosidase levels and is shown on the ordinate. In B, MCF-7 and
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MG-15-CAT reporter and a f3-galactosidase plasmid. CAT results were normalized to /-galactosidase activity. These experiments were repeated
with similar findings. Vector-transfected cells gave similar results to those obtained with MCF-7 cells.
stimulate activation of the PG-13-CAT reporter construct. Thus,
despite the significant Cipl induction in TPA-treated MCF-7
cells, p53-dependent transcriptional activity diminished after
exposure to the phorbol ester.
Rb hypophosphorylation in TPA-treated MCF-7 and MCF-
7-PKC-a cells. Cipl inhibition of the cyclin-dependent kinase
activities leading to a reduced level of Rb phosphorylation is
involved in mediating growth arrest at the G1-S boundary (48).
To examine whether differences in Rb phosphorylation could
explain the altered cell cycle progression in TPA-treated MCF-
7-PKC-a cells, Western blot analysis was done to determine the
phosphorylation status of this protein (Fig. 14). Nearly complete
hypophosphorylation of Rb was induced by TPA treatment in
MCF-7 cells. In contrast, TPA treatment of MCF-7-PKC-a cells
produced only a partial degree of Rb hypophosphorylation. Thus,
extensive hypophosphorylation of Rb in TPA-treated MCF-7
cells was associated with sustained, high levels of Cipl expres-
sion. In addition, the increase in Cipl expression preceded the
onset of Rb hypophosphorylation in MCF-7 cells. The transient
expression of Cipl in TPA-treated MCF-7-PKC-a cells at only
4 and 8 h after TPA exposure was associated with a much reduced
degree ofRb hypophosphorylation relative to that seen in parental
MCF-7 cells. It is unclear as to whether the lesser degree of
induction or the transient nature of Cip expression was responsi-
ble for the lesser degree of Rb hypophosphorylation in TPA-
treated MCF-7-PKC-a cells.
Discussion
In MCF-7 cells, phorbol esters and, to a lesser degree, bryostatin
I elicit a modest degree of growth inhibition associated with
retention of viability. However, overexpression of PKC-a in
MCF-7 breast cancer cells, either directly or indirectly due to
other phenotypic alterations occurring in these cells, lead to cell
death in response to phorbol esters and low doses of bryostatin
1 rather than the cytostatic effect elicited in the parental MCF-
7 cell. It remains unresolved as to whether overexpression of
PKC-a or the concurrent alterations in the endogenous expres-
sion of other PKC isoforms are responsible for initiating the
death signal. Although generated by overexpression of PKC-a,
MCF-7-PKC-a cells display increases in the and 0 isoforms,
moderate decreases in PKC-6 and -t, and a total abolition of
PKC-iq expression (reference 16 and manuscript in prepara-
tion). Thus, with these concomitant alterations in other PKCs,
it is difficult from the current data to ascribe a direct role for
a or another specific isoform in stimulating death. Lastly, it
remains to be determined whether the mechanisms responsible
for the dissimilar response of TPA-treated MCF-7-PKC-a cells
reside solely within the PKC pathway or are due to alterations
in signaling pathways distal to and stimulated by PKC activation
that regulate induction of death. Nonetheless, these data suggest
that alterations in PKC isoform expression can influence the
molecular switch controlling the decision of a breast cancer cell
to undergo death or differentiation in response to activation of
this pathway.
The ability of bryostatin 1 to exert effects at low doses that
wane or disappear at higher doses has been amply documented
in various cell types (27-32). In addition, the capacity for high
doses of bryostatin 1 to antagonize the cellular effects of TPA
has been described previously (27-29, 32, 33). Thus, similar
concentration-dependent responses and dominant effects over
1882 de Vente et al.
24
, 22
20
18
x 16
W& E
0 X 14
o - 12
c() 10
8
6
4
2
35 r
Cell Parental MCF-7
Duration of Exposure to
1OONM TPA (hr)
MCF-7-PKCa
0 1 2 4 8 24 48 72 0 1 2 4 8 24 48 72
_ip - *0 00
A:t
'j. .0,-oM
--PsAd [X~
It f. .,a
gadd45 :f;^
B Cell:
Duration of Exposure
to 1OONM TPA (hr)
gadd45
TGF-P
Genormic
gadc45 level
normalized to
Genomic
EtBr
MCF-7 MCF-7-PKCcx
0 0.5 12 0 0.5 12
0.79 0.45 0.45 6.98 18.33 11.92
C Krr"(
gadd45
a
Figure 12. TPA treatment induces Cipl in MCF-7 cells and gadd45 in MCF-7-PKC-a cells. MCF-7
and MCF-7-PKC-a cells were exposed to 10 nM TPA for varying times (A). Northern blot analysis
was done with the cDNA probes indicated to the left side of the autoradiogram. Ethidium bromide
staining of the gel is shown beneath the authoradiograms. In B, run-on analysis was done on MCF-
7 and MCF-7-PKC-a cells treated with 100 nM TPA for 0.5 or 12 h (see above the autoradiogram).
Labeled transcripts were hybridized against the cDNAs and genomic DNA as indicated to the left of
the autoradiograms. TGF-f3 is included as an example of a gene whose expression was not altered in
MCF-7-PKC-a or MCF-7 cells by TPA treatment. Beneath the autoradiograms is the densitometric
quantitation of the cDNA signal normalized to genomic DNA. In C, MCF-7-PKC-a cells were exposed
to vehicle or 20 pg/ml cycloheximide (CHX) for 4 h. This exposure was followed by a 4-h treatment
with 10 nM TPA. Northern blot analysis was done with a labeled gadd45 cDNA probe. Ethidium
bromide staining of the gel indicated that roughly equal amounts of RNA were loaded per lane.
Vector-transfected cells yielded similar results as to those obtained with MCF-7 cells.
TPA to those elicited by bryostatin 1 in MCF-7-PKC-a cells
have been reported in other cell types. The molecular mecha-
nisms underlying the effects of bryostatin 1 in MCF-7-PKC-a
cells have yet to be elucidated. In certain cell types, the dose-
dependent responses of bryostatin 1 and the dominant effects of
this agent over TPA have been correlated with more pronounced
downregulation of a specific PKC isoform by bryostatin that is
believed to be required to elicit the cellular response (27, 28).
In other cells, the biphasic cellular response of bryostatin 1
correlates with depletion of a specific PKC isoform at low con-
centrations of this agent and abrogation of downregulation of
the same isoform in cells treated with higher doses of bryostatin
1 (32, 33). Regardless of the mechanism responsible for the
concentration-dependent effects of bryostatin 1 in MCF-7-PKC-
a cells, these results demonstrate that bryostatin 1 may exert
varying degrees of antineoplastic efficacy toward specific forms
or classes of breast neoplasias. Given that MCF-7-PKC-a cells
were generated by overexpression of PKC-a and have multiple
alterations in endogenous PKC isoform expression, it is possible
that alterations in the PKC pathway were essential for inducing
and maintaining the more transformed phenotype exhibited by
MCF-7-PKC-a cells. By downregulating the isoform(s) main-
taining viability of MCF-7-PKC-a cells, TPA and low doses of
bryostatin 1 could interrupt the signal transduction required for
MCF-7-PKC-a cell viability and could induce cell death. Thus,
utilization of the PKC pathway to maintain viability of the
MCF-7-PKC-a cell could render this cell preferentially suscep-
tible to cytotoxic responses elicited by bryostatin 1 and phorbol
esters. Therefore, differences in the clinical efficacy of bryo-
statin 1 among various neoplasias and even within a specific
form of neoplasia, such as breast cancer, could be a function
of the specific mechanisms used by the neoplasia to subvert
normal growth control and to undergo malignant transforma-
tion.
These studies suggested that gadd45 may be involved in
the signal cascade leading to death of MCF-7-PKC-a cells. TPA
induction of gadd45 preceded the onset of MCF-7-PKC-a cell
death. Nuclear run-on studies demonstrated an enhanced basal
level of gadd45 transcription in MCF-7-PKC-a cells that was
further increased within a 30-min exposure to TPA. The ability
of cycloheximide to block TPA-stimulated expression of
gadd45 demonstrated a requirement for ongoing protein synthe-
sis to mediate TPA-induced increases in the levels of this gene.
The mechanisms underlying the transcriptional activation of
gadd45 in MCF-7-PKC-a cells have not yet been delineated.
Phorbol ester-induced expression of gadd45 mRNA transcripts
has not been observed in other cell types (49). Thus, it was
somewhat surprising to observe the robust, immediate response
of this gene to TPA treatment in MCF-7-PKC-a cells. A p53
response element is contained in the gadd45 gene and its expres-
sion is positively regulated by this transcription factor (47).
However, TPA induction of gadd45 in MCF-7-PKC-a cells
occurred in the absence of detectable p53 levels or functional
p53-mediated transcriptional activity. An AP-1 site located in
the third intron near the p53 site is also present in the gadd45
gene (47). However, a role for AP-1-mediated induction of
this gene has not been demonstrated. In addition to implicating
a role for gadd45 in mediating death of TPA-treated MCF-7-
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Figure 13. TPA-induced effects on p53 mRNA content
and activity in MCF-7 and MCF-7-PKC-a cells. Northern
blot analysis of MCF-7 and MCF-7-PKC-a cells treated
with 100 nM TPA for varying times (see above the autora-
diograms) is shown in A. Ethidium bromide staining of
the gel is shown beneath the autoradiogram. In B and C,
MCF-7 and MCF-7-PKC-a cells were transiently
transfected with either the p53-responsive PG-13-CAT or
the mutated, non-p53-responsive MG-15-CAT reporters
and treated with different TPA concentrations for 48 h (B)
or with 100 nM TPA for different times (C). CAT activity,
shown on the ordinate, was normalized to ,3-galactosidase
levels. Transfections were done in triplicate and were re-
peated in separate experiments.
PKC-a cells, these findings demonstrate the existence of a phor-
bol ester-activated, p53-independent pathway that can regulate
expression of this gene.
While MCF-7 cells contained readily measurable amounts
of p53 mRNA transcripts and protein, this transcriptional factor
was not detected in MCF-7-PKC-a cells. Southern blot analysis
did not identify a gross gene rearrangement that could account
for the absence of p53. Transient transfection analysis using the
p53 promoter-CAT construct demonstrated an almost complete
lack of transcriptional activation of this promoter in MCF-7-
PKC-a cells relative to the levels detected in MCF-7 cells.
Thus, the decline of p53 in MCF-7-PKC-a cells was mediated,
in part, by decreases in the transcriptional activation of this
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Figure 14. Rb phosphorylation in TPA-treated MCF-7 and MCF-7-
PKC-a cells. Western blot analysis using Rb antiserum was done on
MCF-7 and MCF-7-PKC-a cells treated with 100 nM TPA for varying
times (see above the autoradiogram). Vector-transfected cells yielded
similar results to those obtained with MCF-7 cells.
gene. Given the predominance of other well described mecha-
nisms that inhibit p53 function in human tumors, the signifi-
cance of whether a decrease in the transcription of this gene as
a clinically important phenomenon in human neoplasia remains
uncertain. However, these findings do suggest an interaction
between the PKC pathway and p53 transcriptional regulation.
Lending further support for such an interaction was the ability of
TPA to downregulate p53 mRNA transcripts with a concomitant
decrease in p53 functional activity as assessed by the transient
transfection studies with the PG-13 CAT reporter in MCF-7
cells. A similar TPA-induced decrease in p53 mRNA transcripts
has been noted in HeLa and A549 cells (50).
In MCF-7 cells, TPA treatment rapidly stimulated increases
in expression of Cipl. The functional significance of induction
of this cyclin-dependent kinase interacting protein was apparent
in the hypophosphorylated state of Rb and the accumulation of
MCF-7 cells in G1. Transcriptional activation of Cipl can occur
via a p53-dependent mechanism (39-41). Recently, p53-inde-
pendent modes of inducing Cipl expression have been de-
scribed (51-53). Our findings provide evidence to suggest that
while MCF-7 cells contain p53, activation of the transcriptional
activity of this protein may not be responsible for mediating
TPA-induced Cipl expression. After TPA treatment, p53
mRNA levels declined. In addition, we were unable to detect
functional evidence demonstrating an increase in p53-dependent
transcriptional activity using transient transfectional analysis
with the p53-responsive PG-13-CAT reporter. Furthermore,
TPA did not induce the same degree of increase in another
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p53-responsive gene, gadd45, in MCF-7 cells. Thus, these data
suggest that TPA-induced expression of Cipl in MCF-7 cells
may occur by a p53-independent mechanism. The ability of
PKC-directed signal transduction to stimulate certain aspects of
p53-dependent gene expression would provide a novel means
of altering p53-dependent gene transcription in the absence of
a functional p53 molecule. A better understanding of the mecha-
nisms by which the PKC pathway can elicit these responses
could yield important findings on which to base the design of
therapeutic modalities to treat p53-negative neoplasms that are
resistant to radiation and certain forms of chemotherapy.
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